We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength
Read MoreHide Full Article
Key Takeaways
GILD now expects 2026 product sales excluding Veklury of $29.8B-$30.1B after stronger HIV growth.
Gilead said quarterly PrEP sales topped $1B for the first time, while Biktarvy sales rose 7% to $3.8B.
Trodelvy sales rose 26%, while GILD said two additional commercial launches could arrive in the second half.
Gilead Sciences, Inc. (GILD - Free Report) used its second-quarter 2026 call to emphasize stronger base-business growth, led by HIV, PrEP, Trodelvy and Livdelzi, while outlining a busy second-half launch calendar.
Non-GAAP loss per share was $6.75, better than the Zacks Consensus Estimate for a loss of $7.07. Revenues of $7.8 billion also topped the $7.37 billion consensus and increased 10% year over year.
Gilead Sciences, Inc. Price, Consensus and EPS Surprise
Executive vice president and chief financial officer Andrew Dickinson said GILD now expects 2026 product sales excluding Veklury of $29.8 billion to $30.1 billion, up $350 million at the midpoint from May guidance.
Dickinson said full-year HIV sales are now expected to rise 9% to 10% compared with the prior 8% outlook, reflecting strength in Biktarvy, Yeztugo and Descovy.
Moreover, Dickinson raised the lower end of total product sales guidance to $30.1 billion, leaving the high end at $30.4 billion. Veklury expectations fell to approximately $300 million from about $600 million.
Gilead Leans on HIV and PrEP Momentum
Chairman and chief executive officer Daniel O'Day said HIV sales increased 12% and quarterly PrEP sales exceeded $1 billion for the first time, putting the prevention business at a $4 billion annual run rate.
Chief commercial and corporate affairs officer Johanna Mercier said Biktarvy sales rose 7% to $3.8 billion, while Yeztugo generated $232 million. Gilead maintained its approximately $1 billion full-year Yeztugo sales target.
Mercier also said more than 70% of Yeztugo users returned for reinjection at six months. She expects HIV treatment market growth to return to its typical 2% to 3% annual rate after softer second-quarter trends.
GILD Pushes Oncology and Cell Therapy Launches
O'Day said Trodelvy sales rose 26% year over year, supported by breast cancer demand and new first-line metastatic triple-negative breast cancer approvals.
Mercier said cell therapy sales declined 14% amid ongoing competitive pressure, while launch preparations are underway for anito-cel ahead of its Dec. 23 regulatory decision.
Chief medical officer Dietmar Berger highlighted GS-8824 data in platinum-resistant ovarian cancer, including a 61% confirmed objective response rate and 11-month median progression-free survival across select doses. Registrational development could begin as early as 2027.
Gilead Defends PrEP Breadth and Diversification
A BMO Capital Markets analyst asked whether development of once-weekly oral PrEP reflected weaker enthusiasm for twice-yearly injections. Mercier said the strategy instead addresses patients who prefer oral therapy.
Mercier noted that roughly 80% to 85% of the market remains on daily oral options. She described weekly oral lenacapavir as complementary to Yeztugo rather than a substitute.
A Citigroup analyst asked whether reducing HIV concentration remains a long-term objective. O'Day replied that diversification remains a goal both within virology and through expansion in oncology and immunology.
GILD Shifts From Deals to Integration
Dickinson said Gilead does not currently anticipate additional sizable M&A in 2026 after completing the Arcellx, Tubulis and Ouro Medicines acquisitions.
Dickinson also said near-term priorities center on integrating the acquired programs and platforms. Acquired IPR&D expenses totaled $11.2 billion in the second quarter, primarily reflecting the three transactions.
Dickinson added that GILD returned nearly $1.4 billion to shareholders during the quarter, including $355 million of share repurchases, while operating cash flow totaled $3.6 billion.
Gilead Enters Back Half With Launch Focus
O'Day said the second half could bring two additional commercial launches, BIC/LEN in HIV treatment and anito-cel in multiple myeloma, alongside continued clinical execution.
Management's focus coming out of the call centers on sustaining base-business growth, integrating recent acquisitions and advancing a broader pipeline across HIV, oncology and inflammation.
GILD Zacks Signals Show Mixed Near-Term Profile
GILD carries a Zacks Rank #3 (Hold), with a Value Score of C, Growth Score of C, Momentum Score of A and VGM Score of B. The Style Score framework places A and B grades above C, making momentum the strongest individual style signal.
The Zacks framework treats the Rank as the primary short-term indicator, while Style Scores complement it over a similar one-to-three-month horizon. The Zacks Rank can change as analysts revise earnings estimates following the just-reported results.
View the Zacks #1 Rank List
Image: Bigstock
GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength
Key Takeaways
Gilead Sciences, Inc. (GILD - Free Report) used its second-quarter 2026 call to emphasize stronger base-business growth, led by HIV, PrEP, Trodelvy and Livdelzi, while outlining a busy second-half launch calendar.
Non-GAAP loss per share was $6.75, better than the Zacks Consensus Estimate for a loss of $7.07. Revenues of $7.8 billion also topped the $7.37 billion consensus and increased 10% year over year.
Gilead Sciences, Inc. Price, Consensus and EPS Surprise
Gilead Sciences, Inc. price-consensus-eps-surprise-chart | Gilead Sciences, Inc. Quote
GILD Raises Base Business Outlook
Executive vice president and chief financial officer Andrew Dickinson said GILD now expects 2026 product sales excluding Veklury of $29.8 billion to $30.1 billion, up $350 million at the midpoint from May guidance.
Dickinson said full-year HIV sales are now expected to rise 9% to 10% compared with the prior 8% outlook, reflecting strength in Biktarvy, Yeztugo and Descovy.
Moreover, Dickinson raised the lower end of total product sales guidance to $30.1 billion, leaving the high end at $30.4 billion. Veklury expectations fell to approximately $300 million from about $600 million.
Gilead Leans on HIV and PrEP Momentum
Chairman and chief executive officer Daniel O'Day said HIV sales increased 12% and quarterly PrEP sales exceeded $1 billion for the first time, putting the prevention business at a $4 billion annual run rate.
Chief commercial and corporate affairs officer Johanna Mercier said Biktarvy sales rose 7% to $3.8 billion, while Yeztugo generated $232 million. Gilead maintained its approximately $1 billion full-year Yeztugo sales target.
Mercier also said more than 70% of Yeztugo users returned for reinjection at six months. She expects HIV treatment market growth to return to its typical 2% to 3% annual rate after softer second-quarter trends.
GILD Pushes Oncology and Cell Therapy Launches
O'Day said Trodelvy sales rose 26% year over year, supported by breast cancer demand and new first-line metastatic triple-negative breast cancer approvals.
Mercier said cell therapy sales declined 14% amid ongoing competitive pressure, while launch preparations are underway for anito-cel ahead of its Dec. 23 regulatory decision.
Chief medical officer Dietmar Berger highlighted GS-8824 data in platinum-resistant ovarian cancer, including a 61% confirmed objective response rate and 11-month median progression-free survival across select doses. Registrational development could begin as early as 2027.
Gilead Defends PrEP Breadth and Diversification
A BMO Capital Markets analyst asked whether development of once-weekly oral PrEP reflected weaker enthusiasm for twice-yearly injections. Mercier said the strategy instead addresses patients who prefer oral therapy.
Mercier noted that roughly 80% to 85% of the market remains on daily oral options. She described weekly oral lenacapavir as complementary to Yeztugo rather than a substitute.
A Citigroup analyst asked whether reducing HIV concentration remains a long-term objective. O'Day replied that diversification remains a goal both within virology and through expansion in oncology and immunology.
GILD Shifts From Deals to Integration
Dickinson said Gilead does not currently anticipate additional sizable M&A in 2026 after completing the Arcellx, Tubulis and Ouro Medicines acquisitions.
Dickinson also said near-term priorities center on integrating the acquired programs and platforms. Acquired IPR&D expenses totaled $11.2 billion in the second quarter, primarily reflecting the three transactions.
Dickinson added that GILD returned nearly $1.4 billion to shareholders during the quarter, including $355 million of share repurchases, while operating cash flow totaled $3.6 billion.
Gilead Enters Back Half With Launch Focus
O'Day said the second half could bring two additional commercial launches, BIC/LEN in HIV treatment and anito-cel in multiple myeloma, alongside continued clinical execution.
Management's focus coming out of the call centers on sustaining base-business growth, integrating recent acquisitions and advancing a broader pipeline across HIV, oncology and inflammation.
GILD Zacks Signals Show Mixed Near-Term Profile
GILD carries a Zacks Rank #3 (Hold), with a Value Score of C, Growth Score of C, Momentum Score of A and VGM Score of B. The Style Score framework places A and B grades above C, making momentum the strongest individual style signal.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks framework treats the Rank as the primary short-term indicator, while Style Scores complement it over a similar one-to-three-month horizon. The Zacks Rank can change as analysts revise earnings estimates following the just-reported results.